Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial
- 1 October 2008
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Anti-Cancer Drugs
- Vol. 19 (9), 911-915
- https://doi.org/10.1097/cad.0b013e3283099e71
Abstract
We conducted a phase II study to determine the availability and safety of combination chemotherapy with weekly paclitaxel and doxifluridine (a capecitabine metabolite) in the treatment of advanced or recurrent breast cancer. Patients were treated with a combination chemotherapy regimen: doxifluridine was orally administered at 800 mg/day for 14 days, followed by a 7-day washout period. Paclitaxel was given intravenously on days 1 and 8 at 80 mg/m2 for 1 h, followed by a 1-week washout period. This 3-week cycle of therapy was repeated as long as possible (at least eight cycles) until the progression of the tumor and drug-related adverse effects were no longer observed. From May 2003 to December 2005, 26 patients were enrolled in the study. The overall response rate was 53.8% (95% confidence interval, 33.4-73.4%). The clinical benefit rate, including long-term no change, was 65.4% (95% confidence interval, 44.3-82.8%). Time to progression and survival time were 297 and 1182 days, respectively, for the 26 enrolled patients. No severe toxicities were observed. Grade 3/4 leucopenia in three patients, neutropenia in five patients, increased serum creatinine in three patients, hypercalemia in one patient, hypocalcemia in one patient, nausea/vomiting in two patients, and diarrhea in one patient. The good response rate and long time to progression and overall survival time of this doxifluridine combined with weekly paclitaxel therapy indicate its potential as a first-line or second-line treatment for advanced or recurrent breast cancer patients.Keywords
This publication has 11 references indexed in Scilit:
- Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trialEuropean Journal Of Cancer, 2004
- Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast CancerJournal of Clinical Oncology, 2001
- Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancerAnti-Cancer Drugs, 2000
- Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5?-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor modelsInternational Journal of Cancer, 1999
- Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.Journal of Clinical Oncology, 1998
- Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancerAnti-Cancer Drugs, 1998
- CAF in metastatic breast cancer: standard therapy or another effective regimen?Journal of Clinical Oncology, 1987
- Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosidesJournal of Medicinal Chemistry, 1979
- Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifoliaJournal of the American Chemical Society, 1971